Those afflicted with sickle cell disease face many challenges and acute complications. This biopharma company is the leader in treatment of the disease and just reported its fifth straight increase in quarterly net revenues. 

Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Increased sales in the U.S. and Middle East/North Africa region helped the firm report a fifth straight increase in quarterly net revenues and increased net revenues of 109% year-over-year. 

Due to these increases the firm was able to substantially reduce losses from operations and realized income from operations excluding share-based compensation. The firm’s product, Endari® (L-glutamine oral powder), is indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar and the United Arab Emirates and is available on a named patient or early access basis in France, the Netherlands. Shares last traded at $0.32.